← Leaderboards
Jo-Ann Shelley Passmore
Centre/Aids Programme/Res/South Africa
$3,209,328
Attributed
$4,316,254
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2014–20$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,316,254 · 3
By mechanism
R01$4,255,774 · 2
D71$60,480 · 1
Top collaborators
- Heather Beryl Jaspan4 shared
- Lyle Mckinnon2 shared
Most similar at Centre/Aids Programme/Res/South Africa
Same institution · by research overlap
- Quarraisha Abdool Karim$35,100,516
- Sinaye Ngcapu$792,098
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventSouthern AfricaCytokineImmunologyAffectYoung WomanCellsHiv RiskPhenotypeMucous MembraneImmunityLinkInflammationInflammatoryGenital SystemClinical TrialsAfrica South Of The SaharaHiv InfectionsVaginaWomanPredispositionLaboratoriesUniversitiesDesign
Grant awards (10)
Mucosal injury from sexual practices: Behaviour and biology of South African adolescents$600,593
R01 · FY2020 · AI
Mucosal injury from sexual practices: Behaviour and biology of South African adolescents$583,595
R01 · FY2019 · AI
Mucosal injury from sexual practices: Behaviour and biology of South African adolescents$483,323
R01 · FY2018 · AI
Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004$538,081
R01 · FY2017 · AI · contact PI
Mucosal injury from sexual practices: Behaviour and biology of South African adolescents$485,861
R01 · FY2017 · AI
Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004$538,081
R01 · FY2016 · AI · contact PI
Building Systems Biology Capacity at CAPRISA to understand HIV transmission risk$30,240
D71 · FY2016 · TW · contact PI
Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004$566,160
R01 · FY2015 · AI · contact PI
Building Systems Biology Capacity at CAPRISA to understand HIV transmission risk$30,240
D71 · FY2015 · TW · contact PI
Inflammation and HIV risk: understanding partial Tenofovir efficacy in CAPRISA004$460,080
R01 · FY2014 · AI · contact PI